Limits...
Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.

Saxenian H, Hecht R, Kaddar M, Schmitt S, Ryckman T, Cornejo S - Health Policy Plan (2014)

Bottom Line: Although all possess certain strengths, each country displayed weaknesses in some of the following areas: budgeting for vaccine purchase, national procurement practices, performance of national regulatory agencies, and technical capacity for vaccine planning and advocacy.The 2012 pilot experience further demonstrated the value of transition planning processes and tools.As a result, GAVI has decided to continue with transition planning in 2013 and beyond.

View Article: PubMed Central - PubMed

Affiliation: Consultant to Results for Development Institute, Washington, DC 20005, USA, Results for Development Institute, Washington, DC 20005, USA, World Health Organization, 1211 Geneva, Switzerland, Consultant to World Health Organization, 1211 Geneva, Switzerland, GAVI Alliance, 1202 Geneva, Switzerland rhecht@resultsfordevelopment.org.

No MeSH data available.


Related in: MedlinePlus

Countries graduating from GAVI support: 2011 GNI per capita, 2011 public spending on health per capita, and number of new vaccines adopted or pending adoption with GAVI support. Note: The smallest bubble represents one vaccine adopted or pending adoption with GAVI support; the largest represents four vaccines.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4325534&req=5

czu003-F2: Countries graduating from GAVI support: 2011 GNI per capita, 2011 public spending on health per capita, and number of new vaccines adopted or pending adoption with GAVI support. Note: The smallest bubble represents one vaccine adopted or pending adoption with GAVI support; the largest represents four vaccines.

Mentions: The funds that graduating countries will need to budget for vaccines will depend on the number of new vaccines they have introduced with GAVI support, the quantity of doses required and initially on co-financing requirements. After GAVI financing ends, domestic resource needs will also be driven by the price of the particular vaccine for its specific presentation (single dose vs multi-dose vials, in liquid vs freeze-dried form, etc.). Four of the 14 countries have GAVI funding for only one vaccine—pentavalent (see Figure 2); four have adopted two vaccines with GAVI financing, and five have GAVI support for three vaccines. The Republic of Congo has the largest bubble in Figure 2, as it has obtained GAVI funds to introduce four vaccines.Figure 2


Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.

Saxenian H, Hecht R, Kaddar M, Schmitt S, Ryckman T, Cornejo S - Health Policy Plan (2014)

Countries graduating from GAVI support: 2011 GNI per capita, 2011 public spending on health per capita, and number of new vaccines adopted or pending adoption with GAVI support. Note: The smallest bubble represents one vaccine adopted or pending adoption with GAVI support; the largest represents four vaccines.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4325534&req=5

czu003-F2: Countries graduating from GAVI support: 2011 GNI per capita, 2011 public spending on health per capita, and number of new vaccines adopted or pending adoption with GAVI support. Note: The smallest bubble represents one vaccine adopted or pending adoption with GAVI support; the largest represents four vaccines.
Mentions: The funds that graduating countries will need to budget for vaccines will depend on the number of new vaccines they have introduced with GAVI support, the quantity of doses required and initially on co-financing requirements. After GAVI financing ends, domestic resource needs will also be driven by the price of the particular vaccine for its specific presentation (single dose vs multi-dose vials, in liquid vs freeze-dried form, etc.). Four of the 14 countries have GAVI funding for only one vaccine—pentavalent (see Figure 2); four have adopted two vaccines with GAVI financing, and five have GAVI support for three vaccines. The Republic of Congo has the largest bubble in Figure 2, as it has obtained GAVI funds to introduce four vaccines.Figure 2

Bottom Line: Although all possess certain strengths, each country displayed weaknesses in some of the following areas: budgeting for vaccine purchase, national procurement practices, performance of national regulatory agencies, and technical capacity for vaccine planning and advocacy.The 2012 pilot experience further demonstrated the value of transition planning processes and tools.As a result, GAVI has decided to continue with transition planning in 2013 and beyond.

View Article: PubMed Central - PubMed

Affiliation: Consultant to Results for Development Institute, Washington, DC 20005, USA, Results for Development Institute, Washington, DC 20005, USA, World Health Organization, 1211 Geneva, Switzerland, Consultant to World Health Organization, 1211 Geneva, Switzerland, GAVI Alliance, 1202 Geneva, Switzerland rhecht@resultsfordevelopment.org.

No MeSH data available.


Related in: MedlinePlus